Cargando…

Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol‐containing oral contraceptive in healthy adult women

AIMS: This study aimed to investigate whether cabotegravir (CAB), an integrase inhibitor in development for treatment and prevention of human immunodeficiency virus‐1, influences the pharmacokinetics (PK) of a levonorgestrel (LNG) and ethinyl oestradiol (EO)–containing oral contraceptive (OC) in hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trezza, Christine, Ford, Susan L., Gould, Elizabeth, Lou, Yu, Huang, Chuyun, Ritter, James M., Buchanan, Ann M., Spreen, William, Patel, Parul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Drug Interactions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465324/ https://www.ncbi.nlm.nih.gov/pubmed/28087972 http://dx.doi.org/10.1111/bcp.13236

Ejemplares similares

Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
por: Kapitza, Christoph, et al.
Publicado: (2015)

The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives
por: Bonnema, Rachel A., et al.
Publicado: (2011)

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
por: Ankrom, Wendy, et al.
Publicado: (2018)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Absence of Drug‐Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial
por: Nave, Rüdiger, et al.
Publicado: (2019)

No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
por: Heger-Mahn, Doris, et al.
Publicado: (2014)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
por: Lou, Yu, et al.
Publicado: (2016)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions
por: Wring, Stephen, et al.
Publicado: (2018)

Cabotegravir
Publicado: (2022)

Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval
por: Nappi, Rossella E, et al.
Publicado: (2017)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
por: Gupta, Neeraj, et al.
Publicado: (2017)

The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg
por: Krishnan, Sheila, et al.
Publicado: (2010)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol
por: Song, Ivy H., et al.
Publicado: (2015)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls
por: Shaik, Jafar Sadik B., et al.
Publicado: (2019)

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants
por: Parasrampuria, Ridhi, et al.
Publicado: (2019)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
por: Tan, Jerry KL, et al.
Publicado: (2010)

A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
por: Ankrom, Wendy, et al.
Publicado: (2021)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function
por: Ågren, Ulla M, et al.
Publicado: (2011)

The effect of in utero ethinyl oestradiol exposure on the risk of cryptorchid testis and testicular teratoma in mice.
por: Walker, A. H., et al.
Publicado: (1990)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Relationship between blood alcohol concentration on admission and outcome in dimethoate organophosphorus self-poisoning
por: Eddleston, Michael, et al.
Publicado: (2009)

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects
por: Kubitza, Dagmar, et al.
Publicado: (2014)

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects
por: Song, Ivy, et al.
Publicado: (2015)

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
por: Liu, Yong, et al.
Publicado: (2014)

Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen
por: Zhao, Yanli, et al.
Publicado: (2015)

Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator
por: Williams, Daphne, et al.
Publicado: (2016)

Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials
por: Majid, Oneeb, et al.
Publicado: (2016)

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
por: Parasrampuria, Dolly A., et al.
Publicado: (2016)

Effect of fermented red ginseng on cytochrome P450 and P‐glycoprotein activity in healthy subjects, as evaluated using the cocktail approach
por: Kim, Min‐Gul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_igcgiufh0nkkkspd1vg95mh2a3